Prostate Specific Antigen Features
Although several biomarkers show promise, PCA3 has garnered substantial attention following FDA approval and its role in the diagnosis of PCa will grow.
Latest Prostate Specific Antigen News
Primary care screening patterns have changed as a result of the USPSTF recommendation.
Biopsies triggered by an abnormal DRE alone were significantly less likely to detect clinically significant prostate cancer than biopsies triggered by an abnormal PSA alone.
Patients with higher PSA, shorter PSA doubling time more likely to have second bone scan.
In a small study of mCRPC patients, the median time on therapy increased by nearly 100 days and PSA declined in some subjects.
Guideline outlines recommended follow-up care for prostate cancer survivors
Just over 41% of patients eligible for active surveillance by European standards were found to have undergraded prostate cancer.
PSA doubling time of 6 months or less and seminal vesicle invasion were significant predictors of biochemical recurrence.
New study examined the effect of a U.S. Preventive Services Task Force 2012 recommendation against routine PSA screening.
Diagnostic usefulness of magnetic resonance imaging/ultrasound (MRI/US) fusion targeted prostate biopsy optimized in PSA level of 5.2 ng/mL or higher.
Greater PSA increases seen in older men and those with lower baseline testosterone.
PSA levels at day 30 found to predict biochemical relapse risk in men with positive surgical margins.
Men who had PSA relapse after receiving post-radical surgery salvage radiation therapy had a median overall survival of nearly 14 years.
New study highlights the importance of digital rectal examinations in PCa patients with normal-range PSA at diagnosis.
Reduced likelihood of biochemical recurrence of prostate cancer also linked to concomitant hormonal therapy and positive surgical margins.
Transient rises in PSA after radiotherapy may be due to late damage to healthy prostatic tissue, evidence suggests.
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)